Evotec signed a transaction agreement with Sanofi to integrate Sanofi’s infectious disease unit into its organisation. Evotec will also licence-in the majority of Sanofi’s infectious disease research portfolio and initiatives.
Evotec AG announced that it has expanded its CRISPR service offering with the addition of a licence from ERS Genomics Limited. With this licence, Evotec gains access to the leading technology for gene editing.
Evotec AG has launched its accelerated drug development service INDiGO. With the launch of INDiGO, Evotec’s expertise and capabilities are uniquely combined to deliver better drug candidates faster and more efficiently.